AllSci News
Gilead finalizes up to USD 5b acquisition of Tubulis' ADC platform
Gilead Sciences (Nasdaq: GILD) has completed its acquisition of Tubulis GmbH, a clinical-stage biotechnology company based in Munich, Germany, adding a...
Kelun-Biotech's sacituzumab tirumotecan meets primary endpoint in Phase III advanced triple-negative breast cancer trial
Sichuan Kelun-Biotech Biopharmaceutical Co. (HKEx: 6990.HK) announced that its TROP2-directed antibody-drug conjugate sacituzumab tirumotecan met the...
Immix Bio's BCMA CAR-T achieves 95% complete response rate in Phase II AL amyloidosis trial
Immix Biopharma (Nasdaq: IMMX) reported a 95% complete response rate in an interim update from its AL amyloidosis clinical trial, with 19 of 20 evaluable...
Junshi, Remegen pick up China nod for toripalimab plus disitamab vedotin in HER2+ urothelial carcinoma
Shanghai Junshi Biosciences (HKEX: 1877; SSE: 688180) has received approval from China’s National Medical Products Administration (NMPA) for Tuoyi (toripalimab) in combination…
NMPA approves HutchMed and Innovent’s Elunate and Tyvyt combination for renal cell carcinoma
HutchMed (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) and Innovent Biologics (HKEX: 1801) jointly announced that China’s National Medical Products Administration (NMPA) has…
Eli Lilly's retatrutide achieves 'surgery-like' 28.3% weight loss in Phase III obesity trial
Eli Lilly (NYSE: LLY) reported that retatrutide, its investigational GIP, GLP-1, and glucagon triple hormone receptor agonist, produced a mean body weight...
Imperagen closes GBP 5 million seed round for quantum-powered enzyme engineering
Imperagen closes GBP 5 million seed round to scale enzyme engineering platform
Immunovant posts hopeful data for FcRn inhibitor in rheumatoid arthritis post batoclimab failure
Immunovant (Nasdaq: IMVT) reported preliminary Week 16 data from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis, showing ACR20, ACR50, and...
EpiCypher and New England Biolabs expand epigenomics tools partnership with international distribution
EpiCypher (Durham, NC) and New England Biolabs (Ipswich, MA) announced an expanded strategic partnership on covering co-development of next-generation epigenomics research tools…
Duke University supported with USD 1.17m from NIH for combined T cell and B cell HIV immunotherapy
Duke University has received a USD 1.17 million NIH R56 award from the National Institute of Allergy and Infectious Diseases to advance…
Duke University receives USD 1.81m NIH grant for LRRK2 kinase biomarker research in neurodegeneration
Duke University has received a USD 1.81 million NIH RF1 grant from the National Institute of Neurological Disorders and Stroke to investigate how LRRK2...
University of Georgia receives USD 1.3m NIH grant for Parkinson's disease neuroinflammation research
University of Georgia has received a USD 1.3 million NIH RF1 grant from the National Institute of Neurological Disorders and Stroke to investigate...
CureDuchenne makes second investment in Tevard Bio’s work on DMD suppressor tRNA therapy
CureDuchenne, the Newport Beach, California-based nonprofit venture philanthropy organization, has announced a second investment in Tevard Biosciences to support development of the…
Genethon and Ampersand partner on novel AAV vectors with enhanced tissue specificity
Genethon, the French rare disease gene therapy organization based in Évry, and Ampersand Biomedicines, a Boston-based Flagship Pioneering company, announced a research…
Hyundai Bio claims niclosamide offers hope of treating Ebola, hantavirus in preclinical assays
Hyundai Bioscience reported an Ebola virus IC50 of 0.125 μM for its broad-spectrum antiviral candidate XAFTY (niclosamide), according to a company press...
The AllSci Brief
Systematic R&D and deal news. Daily.